Expression and Clinical Significance of Lymphoid Enhancer-Binding Factor 1 in Acute Leukemias.
10.7534/j.issn.1009-2137.2015.03.055
- Author:
Wan-Ying HUO
1
;
Ju GAO
2
Author Information
1. Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
2. Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. E-mail: gaoju651220@126.com.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Cell Differentiation;
Humans;
Leukemia;
Lymphoid Enhancer-Binding Factor 1;
Prognosis;
Wnt Signaling Pathway;
beta Catenin
- From:
Journal of Experimental Hematology
2015;23(3):888-891
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoid enhancer-binding factor 1 (LEF1), a key downstream effector of Wnt/β-catenin signal transduction pathway, plays a crucial role in the maintenance, proliferation and differentiation of normal hematopoietic stem/progenitor cells through regulating the transcription of its target genes. Aberrant LEF1 expression has been documented in a variety of leukemias, and implicated in the prediction of prognosis. Nevertheless, discrepancies exist regarding the expression level and clinical implication of LEF1 in different types of leukemias, suggesting LEF1 might exert distinct roles in different types of leukemia. In the present article, recent research advances of the relationship of LEF1 and regulation of hematopoiesis and leukemogenesis are reviewed.
